What's right (and wrong) with racially stratified research and therapies.
Sade
Robert M
RM
Medical University of South Carolina, Department of Surgery, Charleston, SC 29425, USA. sader@musc.edu
D001741:Black or African American / Q000235:genetics*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D015415:Biomarkers; D035843:Biomedical Research / Q000592:standards*; D017277:Drug Approval; D004338:Drug Combinations; D004345:Drug Industry; D020022:Genetic Predisposition to Disease / Q000208:ethnology; D014644:Genetic Variation; D006333:Heart Failure / Q000188:drug therapy / Q000208:ethnology / Q000235:genetics; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D007548:Isosorbide Dinitrate / Q000627:therapeutic use; D011287:Prejudice; D044469:Racial Groups / Q000235:genetics*; D016032:Randomized Controlled Trials as Topic / Q000592:standards*; D014481:United States; D014486:United States Food and Drug Administration
D000806:Angiotensin-Converting Enzyme Inhibitors; D015415:Biomarkers; D004338:Drug Combinations; C431665:isosorbide-hydralazine combination; D006830:Hydralazine; D007548:Isosorbide Dinitrate